"Are there too many [immuno-oncology programs]? People with cancer are dying every day – we have a lot of work to do," Incyte Corp. CEO Hervé Hoppenot told BioWorld Today as his firm kicked off Echo-301, a phase III trial testing the oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor epacadostat in combination with Merck & Co. Inc.'s approved anti-PD-1 drug Keytruda (pembrolizumab) as first-line treatment for patients with advanced or metastatic melanoma.